Trials
22 active
27 in total · 25 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Melphalan administered directly to the liver via the Hepatic Delivery System (HDS) infused over a 30 minute period, followed by a 30 minute washout period”In the company’s words, NCT05022901 on ClinicalTrials.gov
- Tested for
- Metastatic Ocular Melanoma, Metastatic Uveal Melanoma, Refractory Metastatic Colorectal Cancer, Metastatic Breast Cancer in the Liver
- Main trialPhase 3
- “Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments. This study will evaluate the safety and effects of the treatment.”In the company’s words, NCT05022901 on ClinicalTrials.gov
- Other names
- Melphalan/PHP · Melphalan · HDS · Trifluridine-tipiracil plus Bevacizumab · Trifluridine-tipiracil
Other drugs for Metastatic Uveal Melanoma
- DarovasertibIDEAYA Biosciences · Phase 3
- AU-011Aura Biosciences · Phase 3
- RP2Replimune, Inc. · Phase 2/3
- EB-DTKN-401Beijing Biotech · Phase 1/2
- DYP688Novartis Pharmaceuticals · Phase 1/2
- RoginolisibiOnctura · Phase 2
Coming up2
- DecPhase 2 trial completes · ClinicalTrials.gov
- May 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials27
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 1 Mar 2024 | An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma | |
| Phase 2Recruiting | Dec 2026 | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | |
| Phase 2Recruiting | May 2029 | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease | |
| Phase 2/3Unknown | Jan 2023 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | |
| Phase 3Halted | not given | International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents | |
| Phase 3Authorised | not given | PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with positive ctDNA after surgery and adjuvant chemotherapy for a high-risk stage II and stage III Colorectal Cancer | |
| Phase 2Authorised | not given | Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway | |
| Phase 2Authorised | not given | TRIFLUOX-DP: Safety of Trifluridine/tipiracil as replacement of fluoropyrimidines (5-fluorouracil and capecitabine) based chemotherapy as first line metastatic colorectal or gastroesophageal cancer regimens in patients with dihydropyrimidine dehydrogenase deficiency: a phase II trial | |
| Phase 3Authorised | not given | Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib. ALL2820 | |
| Phase 4Ended | not given | A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) WITH OR WITHOUT DARATUMUMAB (Dara-VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) WITH OR WITHOUT DARATUMUMAB (Dara-Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) – Real MM | |
| Phase 2Authorised | not given | Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed at least one prior line of palliative chemotherapy - The IKF-AIO Phase IIa BEMARA trial | |
| Phase 2/3Authorised | not given | LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis | |
| Phase 2Authorised | not given | LOGICAN : Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin ± nivolumab versus FOLFOX ± nivolumab in patients with HER2 negative locally advanced, recurrent or metastatic gastric, oesophageal or junctional adenocarcinoma | |
| Phase 2Authorised | not given | A phase 1/2 study exploring the safety and activity of Trifluridine/Tipiracil in combination with Capecitabine and Bevacizumab in metastatic colorectal cancer patients. The TriComB trial | |
| Phase 2Authorised | not given | Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer - FIRE-8 - AIO-KRK/YMO-0519 | |
| Phase 2Authorised | not given | RETINO 2018: conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome | |
| Phase 2Authorised | not given | Sequential immunochemotherapy treatment with Pembrolizumab plus Dendritic Cell (DC) Vaccine followed by Trifluridine/Tipiracil plus Bevacizumab in refractory mismatch-repair-proficient (pMMR) or microsatellite-stable (MSS) metastatic colorectal cancer | |
| Phase 2Authorised | not given | PHASE II STUDY OF TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) ADMINISTERED IN COMBINATION WITH A REDUCED-INTENSITY REGIMEN BASED ON FLUDARABINE AND MELPHALAN AS CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA. | |
| Phase 3Authorised | not given | HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN : Randomised, international and multicentric phase 3 study that evaluates 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma, and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy | |
| Phase 1/2Authorised | not given | (CHOPI) Phase 1b/2 Study Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced Uveal Melanoma. | |
| Phase 2Ended | not given | An open label, multicenter, phase II study of belantamab mafodotin in combination with VRd for the treatment of newly diagnosed transplant eligible multiple myeloma patients | |
| Phase 3Authorised | not given | An open-label, randomised, phase III study comparing trifluridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy (SOLSTICE study). | |
| Phase 2Authorised | not given | "RETINO 2011" : Conservative treatment of patients with retinoblastoma | |
| Phase 3Authorised | not given | Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR | |
| Phase 2Authorised | not given | Efficacy and safety of trifluridin/tipiracil in combination with nanoliposomal irinotecan as a second line therapy in patients with cholangiocarcinoma | |
| Phase 2Authorised | not given | Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma. | |
| Phase 2Ended | not given | A phase 2 study of trifluridine/tipiracil in patients with ER-positive, HER2-negative advanced breast cancer that previously received chemotherapy (BOOG 2019-01 TIBET study) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026